AMEX:VNRX

VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update

ISNES, Belgium, Aug. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter endedJune 30, 2017. Volition management will host a conference call to discuss these results and provide a further business up...

2017-08-10 04:05 1336

VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update

Conference call to take place Thursday, August 10, 2017 at 8:30 am Eastern time ISNES, Belgium, Aug. 3, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced it will host a conference call onThursday, August 10, 2017 at 8:30 am Eastern time to discuss its financial and ope...

2017-08-04 04:30 3024

VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

AUSTIN, Texas, July 19, 2017 /PRNewswire/ -- VolitionRx Limited (Volition; NYSE MKT: VNRX), announced it will host a conference call tomorrow,July 20 at 8:30  AM U.S. Eastern Time to discuss its participation in a large multi-center clinical study with the Great Lakes New England Clinical Validati...

2017-07-20 04:30 1739

Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

AUSTIN, Texas, July 18, 2017 /PRNewswire/ -- Volition America, Inc. (Volition America), a wholly-owned subsidiary of VolitionRx Limited (Volition; NYSE MKT: VNRX), has signed an agreement to participate in a large multi-center clinical study with the Great Lakes New England Clinical Validation Ce...

2017-07-18 18:30 1327

Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

ISNES, Belgium, June 30, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will be presenting at the EuropaColon Advocacy Masterclass and will be exhibiting at the European Society for Medical Oncology Congress on Gastrointestinal Cancer (ESMO GI). EuropaColon works...

2017-06-30 21:22 1840

VolitionRx Limited Corrects an Earlier Announcement

ISNES, Belgium, June 27, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today has issued corrections to certain statements made in the press release issued by the Company onMay 9, 2017 regarding the Company's Nu.Q™ Colorectal Cancer Screening Triage Test. Due to the Company's administra...

2017-06-27 19:30 1150

VolitionRx Limited to Present at Multiple Investor Conferences in June

NAMUR, Belgium, May 26, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it is scheduled to present at multiple investor conferences in June. Dr. Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and ...

2017-05-26 18:30 3395

A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

NAMUR, Belgium, May 18, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced the publication of a research paper entitled "Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer". The study was published in Clinical Epigenetics in collaboratio...

2017-05-18 21:00 3618

VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

NAMUR, Belgium, May 11, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) ("Volition") today announced financial results for the quarter endedMarch 31, 2017 and provided a business update. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "I am delighted with the...

2017-05-11 18:30 2999

VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test

New data confirms prior test results that Volition's novel blood test can accurately detect colorectal cancer and reduce colonoscopies NAMUR, Belgium, May 9, 2017 /PRNewswire/ -- At the Digestive Disease Week 2017 (DDW) inChicago, VolitionRx Limited (NYSE MKT: VNRX) presented results that contin...

2017-05-09 19:30 1765

VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update

Conference call to take place Thursday, May 11, 2017 at 8:30 am Eastern time NAMUR, Belgium, May 8, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will host a conference call onThursday, May 11, 2017 at 8:30 am Eastern time to discuss its financial and operating result...

2017-05-08 20:00 1516

Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

NAMUR, Belgium, April 27, 2017 /PRNewswire/ -- Volition (NYSE MKT: VNRX) has commenced its first study in Asia - an evaluation of the Nu.QTM Colorectal Cancer Triage product in a Taiwanese population of 383 subjects. The study is being conducted with ProfessorChiu Ha...

2017-04-27 19:46 1432

Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory

NAMUR, Belgium, April 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) opened its new research and development facility this week. A video showcasing the new facility and opening event is available to view at http://volitionrx.com/news/video-gallery

2017-04-21 20:26 2889
12345